ABSTRACT

SARS-Cov-2 or the severe acute respiratory syndrome Coronavirus 2, since its appearance in December 2019 in Wuhan City of China, it has not stopped creating disasters in different countries of the world. It has warranted an epidemic outburst of respiratory disease called as Covid-19 by the WHO. To curb the spread of the epidemic, Morocco has put in place drastic measures especially regarding vulnerable groups such as HIV positive-patients receiving antiretroviral therapy (ART). Molecular techniques are considered as the gold standard for the acute SARS-Cov-2 infection diagnosis but serological tests have the potential to verify how much the individual has been exposed to the virus. For the present study, we report a seroprevalence of SARS-Cov-2 specific antibodies among a total of 204 HIV-1 patients admitted for immuno-virological monitoring in the INH in Rabat and 200 healthy Moroccans adults recruited from the National Center for Blood Transfusion in Rabat. Serum samples were tested for IgG antibodies against SARS-Cov-2 nucleoprotein using Architect/Abbott. SARSCov-2 seroreactivity was significantly lower in HIV-1 subjects 7.35% compared to that found in healthy controls 19%. Seroprevalences results highlight an amount of circulating neutralising antibodies among our groups. Serological testing is useful for the identification of asymptomatic infection of SARS-Cov-2. Further serosurveys among other populations and in other regions are under process to inform the public of the Covid-19 epidemic variations in all of the country. Key words: SARS-Cov-2, HIV, seroprevalence
Publication date: 01/12/2021

https://ijbpas.com/pdf/2021/December/MS_IJBPAS_2021_DEC_SPCL_2060.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.12.2060